Sunday, August 25, 2019
Korea’s ST Pharm Receives Support from U.S. NIH for Development of HIV Treatment
A Candidate for HIV Treatment
Korea’s ST Pharm Receives Support from U.S. NIH for Development of HIV Treatment
  • By Choi Moon-hee
  • October 23, 2018, 15:37
Share articles

ST Pharm Co., a Korean pharmaceutical company. announced on Oct. 23 that its  candidate for HIV treatment, "STP03-0404," has been selected as a life science project supported by the National Institute of Health (NIH) of the United States.

ST Pharm Co. is an affiliate of Dong-A Socio Holdings, a holding company that controls Dong-A Pharmaceutical Co. and Dong-A ST. Currently, it is working on STP03-0404 with Emory University in the U.S.

STP03-0404 is a candidate for a new drug that is expected to overcome the limitations of drug resistance in existing HIV infection treatments. The Korea Chemical Institute initiated research on the material and transferred its technology to ST Pharm in September 2016.

The research team will receive about $1.39 million in assistance over the next five years from the U.S. NIH.

"There has been a big improvement in HIV treatment for the past 30 years, but the issue of drug resistance is still serious," an official from ST Pharm said. “The support from the NIH will motivate us to redouble our efforts to develop a new drug for HIV patients.”